MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M

MANNKIND CORP

2024-FY EPS reported $0.10 revenue$285,504,000

Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).
GAAP net income $27.6M ($0.10 EPS basic) vs loss of $11.9M in 2023; non-GAAP net income $67.7M ($0.25 EPS).
Reduced debt principal by $236M, remaining $36M convertible notes; year-end cash $203M.
Afrezza INHALE-1 pediatric trial met primary endpoint; FDA meeting planned 1H 2025 for potential sNDA.
MNKD-101 Phase 3 interim enrollment target expected by YE 2025; MNKD-201 Phase 1 completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.